Concussion-focused Scythian sets market debut

By GREGORY ZELLER // Scythian Biosciences Corp. is going public. The New York City/Toronto-based biotech, led by Great Neck investment banker Jonathan Gilbert on its quest to develop the world’s first pharmaceutical treatment for concussions, will begin trading Aug. 8 on the TSX Venture Exchange, one of Canada’s major stock markets. Projected to open at $8 (Canadian) per share, Scythian Biosciences (ticker symbol “SCYB”) will float upwards of 2.5 million shares – about half of…

Feinstein, Hofstra concussion study exposes a nerve

By GREGORY ZELLER // With concussions and other traumatic brain injuries continuing to make headlines on and off the playing field, Long Island researchers may be closing in on a unique treatment method. Scientists at the Feinstein Institute for Medical Research and the Hofstra Northwell School of Medicine have published the results of a nerve-stimulation study with broad-ranging implications for many neurological conditions, including severe TBIs. Published online by the international science journal Nature, the…

Tackling concussions with cannabis

By GREGORY ZELLER // A research effort stretching from Florida to Long Island to Canada’s Alberta province will determine if compounds derived from marijuana can be effective treatments for concussions. Calgary-based R&D firm Scythian Biosciences has agreed to fund a University of Miami study, to be conducted by the university’s The Miami Project to Cure Paralysis and Miller School of Medicine, exploring cannabinoid-based methods of reducing post-concussion brain cell inflammation, which causes headaches and other neurological complications….